Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31382005 | 0.85 | GPR119 (0.53) | TACR1TSHRALOX15ATMHSD11B1 | |
| SCHEMBL31382358 | 0.84 | TSHR (0.50) | TACR1TSHRALOX15ATMHSD11B1 | |
| SCHEMBL31382470 | 0.84 | TSHR (0.50) | TACR1TSHRALOX15ATMHSD11B1 | |
| SCHEMBL13660794 | 0.84 | TACR1 (0.56) | TACR1TSHROPRM1OPRL1CYP2D6 | |
| SCHEMBL12894223 | 0.84 | OPRM1 (0.50) | OPRM1OPRL1KCNA3 | |
| SCHEMBL971790 | 0.84 | TSHR (0.65) | TACR1TSHRALOX15ATMHSD11B1 | |
| SCHEMBL10246238 | 0.81 | TACR1 (0.53) | TACR1TSHRALOX15ATMMAPT | |
| SCHEMBL703109 | 0.81 | TACR1 (0.61) | TACR1TSHRALOX15ATMHSD11B1 | |
| SCHEMBL15701118 | 0.81 | SLC6A4 (0.51) | MAPTOPRM1OPRL1 | |
| SCHEMBL15807246 | 0.80 | TACR1 (0.52) | TACR1TSHRMAPTOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468368-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-7294628-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2006-07-27 | — | — | US | disclosed |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167007-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C2, NR3C1 | TACR1 96/4885TSHR 64/4885ALOX15 2013/4885 |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C1, CBR1 | TACR1 104/4885TSHR 192/4885ALOX15 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.